{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:54:35Z","timestamp":1764791675792,"version":"3.46.0"},"reference-count":19,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Grading small foci of prostate cancer on a needle biopsy is often difficult, yet the clinical significance of accurate grading remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To assess if grading of limited adenocarcinoma on prostate biopsy specimen is critical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We studied 295 consecutive patients undergoing extended-sextant biopsy with only 1-core involvement of adenocarcinoma, followed by radical prostatectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>The linear tumor lengths on these biopsy specimens were: less than 1 mm (n = 114); 1 mm or more or less than 2 mm (n = 82); 2 mm or more or less than 3 mm (n = 35); and 3 mm or more (n = 64). Longer length was strongly associated with higher Grade Group (GG) on biopsy or prostatectomy specimen, higher risk of extraprostatic extension\/seminal vesicle invasion and positive surgical margin, and larger estimated tumor volume. When cases were compared based on biopsy specimen GG, higher grade was strongly associated with higher prostatectomy specimen GG, higher incidence of pT3\/pT3b disease, and larger tumor volume. Outcome analysis further showed significantly higher risks for biochemical recurrence after radical prostatectomy in patients with 1 mm or more, 2 mm or more, 3 mm or more, GG2-4, GG3-4, GG4, less than 1 mm\/GG2-4, less than 1 mm\/GG3-4, less than 2 mm\/GG3-4, 3 mm or more\/GG2-4, or 3 mm or more\/GG3-4 tumor on biopsy specimens, compared with respective control subgroups. In particular, 3 mm or more, GG3, and GG4 on biopsy specimens showed significance as independent prognosticators by multivariate analysis. Meanwhile, there were no significant differences in the rate of upgrading or downgrading after radical prostatectomy among those subgrouped by biopsy specimen tumor length (eg, &amp;lt;1 mm [44.7%] versus \u22651\/&amp;lt;2 mm [41.5%] versus \u22652\/&amp;lt;3 mm [45.7%] versus \u22653 mm [46.9%]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>These results indicate that pathologists still need to make maximum efforts to grade relatively small prostate cancer on biopsy specimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2020-0835-oa","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T15:19:16Z","timestamp":1642000756000},"page":"469-477","source":"Crossref","is-referenced-by-count":4,"title":["Limited Adenocarcinoma of the Prostate on Needle Core Biopsy"],"prefix":"10.5858","volume":"146","author":[{"given":"Phoenix D.","family":"Bell","sequence":"first","affiliation":[{"name":"From the Department of Pathology & Laboratory Medicine (Bell, Teramoto, Yang, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Teramoto","sequence":"additional","affiliation":[{"name":"From the Department of Pathology & Laboratory Medicine (Bell, Teramoto, Yang, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"},{"name":"The James P. Wilmot Cancer Institute (Teramoto, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik M. S.","family":"Gurung","sequence":"additional","affiliation":[{"name":"The Department of Urology (Gurung, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Yang","sequence":"additional","affiliation":[{"name":"From the Department of Pathology & Laboratory Medicine (Bell, Teramoto, Yang, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"From the Department of Pathology & Laboratory Medicine (Bell, Teramoto, Yang, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"},{"name":"The James P. Wilmot Cancer Institute (Teramoto, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"},{"name":"The Department of Urology (Gurung, Miyamoto), at the University of Rochester Medical Center, Rochester, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"2022031721485101200_i1543-2165-146-4-469-b01","doi-asserted-by":"crossref","unstructured":"Torre\n              LA,\n            \n            \n              Bray\n              F,\n            \n            \n              Siegel\n              RL,\n            \n            \n              Ferlay\n              J,\n            \n            \n              Lortet-Tieulent\n              J,\n            \n            \n              Jemal\n              A.\n            \n          \n          Global cancer statistic, 2012.\n\t\t\t\t\tCA Cancer J Clin.\n\t\t\t\t\t2018;\n\t\t\t\t\t65(2):\n\t\t\t\t\t87\u2013\n\t\t\t\t\t108.","DOI":"10.3322\/caac.21262"},{"key":"2022031721485101200_i1543-2165-146-4-469-b02","doi-asserted-by":"crossref","unstructured":"Bray\n              F,\n            \n            \n              Ferlay\n              J,\n            \n            \n              Soerjomataram\n              I,\n            \n            \n              Siegel\n              RL,\n            \n            \n              Torre\n              LA,\n            \n            \n              Jemal\n              A.\n            \n          \n          Global cancer statistic 2018: GLOBOCAN estimates of incidence and mortality worldwide for 35 cancers in 185 countries.\n\t\t\t\t\tCA Cancer J Clin.\n\t\t\t\t\t2018;\n\t\t\t\t\t68(6):\n\t\t\t\t\t394\u2013\n\t\t\t\t\t424.","DOI":"10.3322\/caac.21492"},{"key":"2022031721485101200_i1543-2165-146-4-469-b03","doi-asserted-by":"crossref","unstructured":"Van den Broeck\n              T,\n            \n            \n              van den Bergh\n              RCN,\n            \n            \n              Briers\n              E,\n            \n            et al.\n          \n          Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations.\n\t\t\t\t\tEur Urol Focus.\n\t\t\t\t\t2020;\n\t\t\t\t\t6(2):\n\t\t\t\t\t231\u2013\n\t\t\t\t\t234.","DOI":"10.1016\/j.euf.2019.06.004"},{"key":"2022031721485101200_i1543-2165-146-4-469-b04","doi-asserted-by":"crossref","unstructured":"Klotz\n              L,\n            \n            \n              Vesprini\n              D,\n            \n            \n              Sethukavalan\n              P,\n            \n            et al.\n          \n          Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t33(3):\n\t\t\t\t\t272\u2013\n\t\t\t\t\t277.","DOI":"10.1200\/JCO.2014.55.1192"},{"key":"2022031721485101200_i1543-2165-146-4-469-b05","doi-asserted-by":"crossref","unstructured":"Tosoian\n              JJ,\n            \n            \n              Mamawala\n              M,\n            \n            \n              Epstein\n              JI,\n            \n            et al.\n          \n          Intermediate and long-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t33(30):\n\t\t\t\t\t3379\u2013\n\t\t\t\t\t3385.","DOI":"10.1200\/JCO.2015.62.5764"},{"key":"2022031721485101200_i1543-2165-146-4-469-b06","doi-asserted-by":"crossref","unstructured":"Epstein\n              JI,\n            \n            \n              Walsh\n              PC,\n            \n            \n              Carmichael\n              M,\n            \n            \n              Brendler\n              CB.\n            \n          \n          Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.\n\t\t\t\t\tJAMA.\n\t\t\t\t\t1994;\n\t\t\t\t\t271(5):\n\t\t\t\t\t368\u2013\n\t\t\t\t\t374.","DOI":"10.1001\/jama.271.5.368"},{"key":"2022031721485101200_i1543-2165-146-4-469-b07","doi-asserted-by":"crossref","unstructured":"Humphrey\n              PA,\n            \n            \n              Baty\n              J,\n            \n            \n              Keetch\n              D.\n            \n          \n          Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy.\n\t\t\t\t\tCancer.\n\t\t\t\t\t1995;\n\t\t\t\t\t75(S7):\n\t\t\t\t\t1842\u2013\n\t\t\t\t\t1849.","DOI":"10.1002\/1097-0142(19950401)75:7+<1842::AID-CNCR2820751614>3.0.CO;2-2"},{"key":"2022031721485101200_i1543-2165-146-4-469-b08","doi-asserted-by":"crossref","unstructured":"Thorson\n              P,\n            \n            \n              Humphrey\n              PA.\n            \n          \n          Minimal adenocarcinoma in prostate needle biopsy tissue.\n\t\t\t\t\tAm J Clin Pathol.\n\t\t\t\t\t2000;\n\t\t\t\t\t114(6):\n\t\t\t\t\t896\u2013\n\t\t\t\t\t909.","DOI":"10.1309\/KVPX-C1EM-142L-1M6W"},{"key":"2022031721485101200_i1543-2165-146-4-469-b09","doi-asserted-by":"crossref","unstructured":"Epstein\n              JI.\n            \n          \n          Diagnosis of limited adenocarcinoma of the prostate.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2012;\n\t\t\t\t\t60(1):\n\t\t\t\t\t28\u2013\n\t\t\t\t\t40.","DOI":"10.1111\/j.1365-2559.2011.03990.x"},{"key":"2022031721485101200_i1543-2165-146-4-469-b10","doi-asserted-by":"crossref","unstructured":"Epstein\n              JI,\n            \n            \n              Feng\n              Z,\n            \n            \n              Trock\n              BJ,\n            \n            \n              Pierorazio\n              PM.\n            \n          \n          Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2012;\n\t\t\t\t\t61(5):\n\t\t\t\t\t1019\u2013\n\t\t\t\t\t1024.","DOI":"10.1016\/j.eururo.2012.01.050"},{"key":"2022031721485101200_i1543-2165-146-4-469-b11","doi-asserted-by":"crossref","unstructured":"Epstein\n              JI,\n            \n            \n              Amin\n              MB,\n            \n            \n              Fine\n              SW,\n            \n            et al.\n          \n          The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer.\n\t\t\t\t\tArch Pathol Lab Med.2021;\n\t\t\t\t\t145(4):\n\t\t\t\t\t461\u2013\n\t\t\t\t\t493.","DOI":"10.5858\/arpa.2020-0015-RA"},{"key":"2022031721485101200_i1543-2165-146-4-469-b12","doi-asserted-by":"crossref","unstructured":"Cohen\n              MS,\n            \n            \n              Hanley\n              RS,\n            \n            \n              Kurteva\n              T,\n            \n            et al.\n          \n          Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2008;\n\t\t\t\t\t54(2):\n\t\t\t\t\t371\u2013\n\t\t\t\t\t381.","DOI":"10.1016\/j.eururo.2008.03.049"},{"key":"2022031721485101200_i1543-2165-146-4-469-b13","doi-asserted-by":"crossref","unstructured":"Sauter\n              G,\n            \n            \n              Steurer\n              S,\n            \n            \n              Clauditz\n              TS,\n            \n            et al.\n          \n          Clinical utility of quantitative Gleason grading in prostate biopsies and prostatectomy specimens.\n\t\t\t\t\tEur Urol.\n\t\t\t\t\t2016;\n\t\t\t\t\t69(4):\n\t\t\t\t\t592\u2013\n\t\t\t\t\t598.","DOI":"10.1016\/j.eururo.2015.10.029"},{"key":"2022031721485101200_i1543-2165-146-4-469-b14","doi-asserted-by":"crossref","unstructured":"Epstein\n              JI,\n            \n            \n              Egevad\n              L,\n            \n            \n              Amin\n              MB,\n            \n            et al.\n          \n          The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system.\n\t\t\t\t\tAm J Surg Pathol.\n\t\t\t\t\t2016;\n\t\t\t\t\t40(2):\n\t\t\t\t\t244\u2013\n\t\t\t\t\t252.","DOI":"10.1097\/PAS.0000000000000530"},{"key":"2022031721485101200_i1543-2165-146-4-469-b15","doi-asserted-by":"crossref","unstructured":"Rubin\n              MA,\n            \n            \n              Dunn\n              R,\n            \n            \n              Kambham\n              N,\n            \n            \n              Misick\n              CP,\n            \n            \n              O'Toole\n              KM.\n            \n          \n          Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy?\n          \n            Am J Surg Pathol\n          .\n\t\t\t\t\t2000;\n\t\t\t\t\t24(12):\n\t\t\t\t\t1634\u2013\n\t\t\t\t\t1640.","DOI":"10.1097\/00000478-200012000-00007"},{"key":"2022031721485101200_i1543-2165-146-4-469-b16","doi-asserted-by":"crossref","unstructured":"Bsirini\n              C,\n            \n            \n              Danakas\n              AM,\n            \n            \n              Miyamoto\n              H.\n            \n          \n          Continuous versus discontinuous tumor involvement: A dilemma in prostate biopsy quantitation.\n\t\t\t\t\tProstate.\n\t\t\t\t\t2018;\n\t\t\t\t\t78(15):\n\t\t\t\t\t1166\u2013\n\t\t\t\t\t1171.","DOI":"10.1002\/pros.23691"},{"key":"2022031721485101200_i1543-2165-146-4-469-b17","doi-asserted-by":"crossref","unstructured":"Wills\n              ML,\n            \n            \n              Sauvageot\n              J,\n            \n            \n              Partin\n              AW,\n            \n            \n              Gurganus\n              R,\n            \n            \n              Epstein\n              JI.\n            \n          \n          Ability of sextant biopsies to predict radical prostatectomy stage.\n\t\t\t\t\tUrology.\n\t\t\t\t\t1998;\n\t\t\t\t\t51(5):\n\t\t\t\t\t759\u2013\n\t\t\t\t\t764.","DOI":"10.1016\/S0090-4295(98)00011-9"},{"key":"2022031721485101200_i1543-2165-146-4-469-b18","doi-asserted-by":"crossref","unstructured":"Yashi\n              M,\n            \n            \n              Mizuno\n              T,\n            \n            \n              Yuki\n              H,\n            \n            et al.\n          \n          Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy.\n\t\t\t\t\tBMC Urol.\n\t\t\t\t\t2014;\n\t\t\t\t\t14:\n\t\t\t\t\t43.","DOI":"10.1186\/1471-2490-14-43"},{"key":"2022031721485101200_i1543-2165-146-4-469-b19","doi-asserted-by":"crossref","unstructured":"Vollmer\n              RT.\n            \n          \n          The importance of tumor length in needle biopsies of the prostate.\n\t\t\t\t\tAm J Clin Pathol.\n\t\t\t\t\t2020;\n\t\t\t\t\t154(4):\n\t\t\t\t\t533\u2013\n\t\t\t\t\t535.","DOI":"10.1093\/ajcp\/aqaa068"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/4\/469\/3030351\/i1543-2165-146-4-469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/146\/4\/469\/3030351\/i1543-2165-146-4-469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:40:49Z","timestamp":1764790849000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/146\/4\/article-p469.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,1,12]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2020-0835-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"type":"electronic","value":"1543-2165"},{"type":"print","value":"0003-9985"}],"subject":[],"published":{"date-parts":[[2022,1,12]]}}}